Target species
Horses and other equines.
Indications for use
A broad spectrum anthelmintic for the treatment and control of adult and immature roundworms of the gastro-intestinal tract in horses and other equines.
The veterinary medicinal product effectively treats and controls the following roundworm infections:
Large strongyles (adults and migrating larval stages of S. vulgaris; adults and tissue larval stages of S. edentatus)
Benzimidazole susceptible adult and immature small strongyles (cyathostomes) including encysted mucosal 3rd and 4th stage larvae and it is also effective against inhibited 3rd stage larvae (encysted) in the mucosa.
Adult and immature Oxyuris spp., Strongyloides spp. and Parascaris equorum.
This veterinary medicinal product has an ovicidal effect on nematode eggs.
Contraindications
None known.
Special warnings for each target species
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:
∙ Too frequent and repeated use of anthelmintic from the same class, over an extended period of time.
∙ Under dosing, which may be due to underestimation of body weight, misadministration of the veterinary medicinal product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Resistance to fenbendazole has been reported in cyathostomes in horses. Therefore, the use of this veterinary medicinal product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintic.
Special precautions for use
Not applicable.
Operator warnings
Direct contact with the skin should be kept to a minimum. Avoid inhalation of granule dust. Wash hands after use.
Adverse reactions
Horses and other equids:
None known.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Use during pregnancy or lactation
Pregnancy:
Pregnant mares and young foals may be safely treated with fenbendazole at therapeutic dosage levels.
Interactions
None known.
Amounts to be administered and administration route
Oral use.
To ensure a correct dosage, bodyweight should be determined as accurately as possible.
The use of suitably calibrated measuring equipment is recommended. Accuracy of the dosing device should be checked.
The veterinary medicinal product should be sprinkled onto concentrate or grain feed and the full dosage given as one administration. It is not necessary to withhold feed before or after treatment.
Routine treatment: Administer orally 5g of the veterinary medicinal product per 150kg bodyweight.
(= 7.5mg fenbendazole/kg bodyweight)
Practical dosage recommendations:
Up to 150 kg: 5 g
151 to 300 kg: 10 g
301 to 450 kg: 15 g
451 to 600 kg: 20 g
601 to 750 kg: 25 g
751 to 900 kg: 30 g
Each sachet contains 10.2 g granules and can be used as follows:
Foals and ponies up to 300 kg bodyweight: 1 sachet
Thoroughbreds and other breeds of horses up to 600 kg bodyweight: 2 sachets
Heavy hunters, heavy draft horses: 3 sachets
Donkeys: 1 sachet
Increased dosing for specific infections
Five-day course:
For the treatment and control of migrating larval stages of large strongyles and encysted mucosal 3rd and 4th stage larvae and inhibited 3rd stage small strongyle larvae (encysted) in the mucosa, administer 5 g of the veterinary medicinal product per 150 kg bodyweight daily for 5 days.
(= 7.5 mg fenbendazole/kg bodyweight daily for 5 days).
Single dose treatments:
For the treatment and control of encysted mucosal stages of small strongyles, administer 20 g of the veterinary medicinal product per 150 kg bodyweight.
(= 30 mg fenbendazole/kg bodyweight).
For the treatment and control of migrating stages of large strongyles, administer 40 g of the veterinary medicinal product per 150 kg bodyweight.
(= 60 mg fenbendazole/kg bodyweight).
Diarrhoea caused by Strongyloides westeri in two- to three-week-old suckling foals should be treated with Panacur 10% Suspension at a dose rate of 25 ml per 50 kg bodyweight.
(= 50 mg fenbendazole per kg bodyweight).
Recommended dosing programme:
Inappropriate use of anthelmintics may increase resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on professional advice and take into account current best practice recommendations for parasite control.
Seek veterinary advice for appropriate monitoring, stock management and dosing programmes to allow optimum endoparasite control.
Overdose
Benzimidazoles are unlikely to cause any reactions in the target species.
Withdrawal periods
Not to be used in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.